Showing results (231-240 of 368) with videos related to
Sort By:
Pageof 37
Circulation. Heart Failure|November 9, 2020
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?Su E Yeoh, Pooja Dewan, Pardeep S Jhund, et al.European Journal of Heart Failure|August 27, 2023
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVERJawad H Butt, Henri Lu, Toru Kondo, et al.JACC. Heart Failure|June 15, 2023
Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection FractionJawad H Butt, Kieran F Docherty, Mikhail N Kosiborod, et al.The Lancet. Diabetes & Endocrinology|November 20, 2020
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trialDarren K McGuire, Bernard Zinman, Silvio E Inzucchi, et al.Journal of the American Heart Association|September 2, 2017
Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®Suzanne V Arnold, Abhinav Goyal, Silvio E Inzucchi, et al.Journal of the American College of Cardiology|April 6, 2022
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized TrialLama Ghazi, Yu Yamamoto, Ralph J Riello, et al.Diabetes, Obesity & Metabolism|March 22, 2023
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trialDarren K McGuire, Rodica P Busui, John Deanfield, et al.JACC. Heart Failure|February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HFKieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.JACC. Heart Failure|May 7, 2025
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 TrialDavid D Berg, Siddharth M Patel, Paul M Haller, et al.Pageof 37